Four lenses on accelerated approvals over time: Data Byte

FDA accelerated approvals are on the rise, in large part due to biomarker-defined drug development and strategic moves into new indications for cancer therapies. 

And though most accelerated approvals in the past four years have yet to be converted to full approval, few of the approvals granted before 2017 remain pending, suggesting companies, for the most part, are meeting their postmarketing commitments...